Skip to main content
. 2019 Sep 4;9(9):223. doi: 10.3390/brainsci9090223

Figure 1.

Figure 1

Differences in ALS survival duration based on ALS onset type and PEG usage. (A) All PEG users (n = 279) had a significantly (p < 0.05) longer disease duration than all non-users (n = 649). (B) Limb onset PEG users (n = 138) had significantly longer disease durations than bulbar onset PEG users (n = 133) (p < 0.05). (C) PEG is associated with a significant increase in survival duration in limb onset PEG users (n = 138) compared to limb onset non-users (n = 448) (p < 0.05). (D) PEG usage is associated with a significant increase in survival duration in bulbar onset PEG users (n = 133) compared to bulbar onset non-users (n = 164) (p < 0.05).